Overview of Monkeypox Virus
Abstract
Monkeypox virus (MPXV) is a close relative of the Variola (smallpox) virus, which was formerly prevalent throughout West and Central Africa. Nonetheless, instances have lately been verified outside of Africa in several nonendemic nations. Considering the COVID-19 pandemic, the World Health Organization (WHO) defined the recent monkeypox spread health emergency for the public for global significance on 23 July 2022. This worldwide community may be in danger because of the increased number of confirmed cases. The monkeypox virus (MPXV), the etiologic agent, was isolated from diseased monkeys in 1959, and its pathogenicity in humans was first documented in the 1970s, primarily in Western and Central African endemic countries. But in 2022, this disease shows extreme return at a never-before-seen rate, raising concerns about its communicative expansion in non-endemic areas and its potential for human-to-human transmission. Healthcare professionals, public health regulators and the general people around the world must possess substantial expertise for such relatively unknown viral diseases to mitigate the situation. Here, a thorough and current pathogenesis overview, epidemiology and clinical characteristics, along with monkeypox therapy is presented. This current review also covers future research fields, vaccine advancements and preventive and control methods for this reemerging viral disease that is currently recognised as a global crisis in public health.
References
León-Figueroa DA, Barboza JJ, Siddiq A, Sah R, Valladares-Garrido MJ, Rodriguez-Morales AJ. Knowledge and attitude towards mpox: Systematic review and meta-analysis. Plos one. 2024 Aug 9;19(8):e0308478. doi: 10.1371/journal.pone.0308478.
Zebardast A, Latifi T, Shafiei-Jandaghi NZ, Gholami Barzoki M, Shatizadeh Malekshahi S. Plausible reasons for the resurgence of Mpox (formerly Monkeypox): an overview. Tropical Diseases, Travel Med Vac. 2023 Dec 25;9(1):23. doi: 10.1186/S40794-023-00209-6.
Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, et al. Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin. 2019 Dec 1;33(4):1027-43. doi: 10.1016/J.IDC.2019.03.001.
Nylund A, Watanabe K, Nylund S, Karlsen M, Saether PA, Arnesen CE, et al. Morphogenesis of salmonid gill poxvirus associated with proliferative gill disease in farmed Atlantic salmon (Salmo salar) in Norway. Arch Virol. 2008 Jul;153:1299-309. doi: 10.1007/S00705-008-0117-7.
Hendrickson RC, Wang C, Hatcher EL, Lefkowitz EJ. Orthopoxvirus genome evolution: the role of gene loss. Viruses. 2010 Sep 15;2(9):1933-67. doi: 10.3390/V2091933.
Lelli D, Lavazza A, Prosperi A, Sozzi E, Faccin F, Baioni L, et al. Hypsugopoxvirus: a novel poxvirus isolated from Hypsugo Savii in Italy. Viruses. 2019 Jun 19;11(6):568. doi: 10.3390/V11060568.
Yang Z, Gray M, Winter L. Why do poxviruses still matter? Cell Biosci. 2021 May 22;11(1):96. doi: 10.1186/S13578-021-00610-8.
Kmiec D, Kirchhoff F. Monkeypox: a new threat? Int J Mol Sci. 2022 Jul 17;23(14):7866. doi: 10.3390/IJMS23147866.
von Magnus P, Andersen EK, Petersen KB, Birch Andersen A. A pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand. 1959 Sep 46;2:156-76. doi: 10.1111/J.1699-0463.1959.TB00328.X.
Arita I, Henderson DA. Smallpox and monkeypox in non-human primates. Bull World Health Organ. 1968;39(2):277-83. PMID: 5303409.
Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593-7. PMID: 4340218.
Patiño LH, Guerra S, Muñoz M, Luna N, Farrugia K, van de Guchte A, et al. Phylogenetic landscape of Monkeypox Virus (MPV) during the early outbreak in New York City, 2022. Emerg. Microbes Infect. 2023 Dec 31;12(1):e2192830. doi: 10.1080/22221751.2023.2192830.
Berthet N, Descorps-Declère S, Besombes C, Curaudeau M, Nkili Meyong AA, Selekon B, et al. Genomic history of human monkey pox infections in the Central African Republic between 2001 and 2018. Sci. Rep. 2021 Jun 22;11(1):13085. doi: 10.1038/S41598-021-92315-8.
Goyal R, Devi M, Gautam RK, Gupta S. A comprehensive review on rising concern of transmission potential of monkeypox virus on healthcare system. J. Pharm. Sci. 2022 Sep 30;12:265-72. doi: 10.35652/IGJPS.2022.12035.
Silenou BC, Tom-Aba D, Adeoye O, Arinze CC, Oyiri F, Suleman AK, et al. Use of surveillance outbreak response management and analysis system for human monkeypox outbreak, Nigeria, 2017–2019. Emerg Infect Dis. 2020 Feb;26(2):345. doi: 10.3201/EID2602.191139.
Lourie B, Bingham PG, Evans HH, Foster SO, Nakano JH, Herrmann KL. Human infection with monkeypox virus: laboratory investigation of six cases in West Africa. Bull World Health Organ. 1972;46(5):633-9. PMID: 4340223.
Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019 Oct 16;13(10):e0007791. doi: 10.1371/JOURNAL.PNTD.0007791.
Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl Trop Dis. 2022 Feb 11;16(2):e0010141. doi: 10.1371/JOURNAL.PNTD.0010141.
Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 2004 Jan 22;350(4):342-50. doi: 10.1056/NEJMOA032299.
Mauldin MR, McCollum AM, Nakazawa YJ, Mandra A, Whitehouse ER, Davidson W, et al. Exportation of monkeypox virus from the African continent. J Infect Dis. 2022 Apr 15;225(8):1367-76. doi: 10.1093/INFDIS/JIAA559.
Nguyen PY, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR. Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017–2020. Emerg Infect Dis. 2021 Apr;27(4):1007. doi: 10.3201/EID2704.203569.
Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A, et al. The 2017 human monkeypox outbreak in Nigeria—report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. PloS one. 2019 Apr 17;14(4):e0214229. doi: 10.1371/JOURNAL.PONE.0214229.
Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis. 2019 Aug 1;19(8):872-9. doi: 10.1016/S1473-3099(19)30294-4.
Hobson G, Adamson J, Adler H, Firth R, Gould S, Houlihan C, et al. Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro Surveill. 2021 Aug 12;26(32):2100745. doi: 10.2807/1560-7917.ES.2021.26.32.2100745.
Rao AK. Monkeypox in a traveler returning from Nigeria—Dallas, Texas, July 2021. MMWR Mortal Wkly Rep. 2022;71. doi: 10.15585/MMWR.MM7114A1.
Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini LE, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Euro Surveill. 2022 Jun 2;27(22):2200421. doi: 10.2807/1560-7917.ES.2022.27.22.2200421.
Duque MP, Ribeiro S, Martins JV, Casaca P, Leite PP, Tavares M, et al. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill. 2022 Jun 2;27(22):2200424. doi: 10.2807/1560-7917.ES.2022.27.22.2200424.
Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, et al. Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022 Jun 2;27(22):2200422. doi: 10.2807/1560-7917.ES.2022.27.22.2200422.
Kluge H, Ammon A. Monkeypox in Europe and beyond–tackling a neglected disease together. Euro Surveill. 2022 Jun 16;27(24):2200482. doi: 10.2807/1560-7917.ES.2022.27.24.2200482.
Masirika LM, Udahemuka JC, Schuele L, Ndishimye P, Otani S, Mbiribindi JB, et al. Ongoing mpox outbreak in Kamituga, South Kivu province, associated with monkeypox virus of a novel Clade I sub-lineage, Democratic Republic of the Congo, 2024. Euro Surveill. 2024 Mar 14;29(11):2400106. doi: 10.2807/1560-7917.ES.2024.29.11.2400106.
Gessain A, Nakoune E, Yazdanpanah Y. Monkeypox. N. Engl. J. Med. 2022 Nov 10;387(19):1783-93. doi: 10.1056/NEJMRA2208860.
Doty JB, Malekani JM, Kalemba LS, Stanley WT, Monroe BP, Nakazawa YU, et al. Assessing monkeypox virus prevalence in small mammals at the human–animal interface in the Democratic Republic of the Congo. Viruses. 2017 Oct 3;9(10):283. doi: 10.3390/V9100283.
Khodakevich L, Jezek Z, Kinzanzka K. Isolation of monkeypox virus from wild squirrel infected in nature. Lancet (London, England). 2003 Sep 22;327(8472):98. doi: 10.1016/S0140-6736(86)90748-8.
Radonić A, Metzger S, Dabrowski PW, Couacy-Hymann E, Schuenadel L, Kurth A, et al. Fatal monkeypox in wild-living sooty mangabey, Côte d’Ivoire, 2012. Emerg. Infect. Dis. 2014 Jun;20(6):1009. doi: 10.3201/EID2006.131329.
Reynolds MG, Doty JB, McCollum AM, Olson VA, Nakazawa Y. Monkeypox re-emergence in Africa: a call to expand the concept and practice of One Health. Anti Infect Ther. 2019 Feb 1;17(2):129-39. doi: 10.1080/14787210.2019.1567330.
Tesh RB, Watts DM, Sbrana E, Siirin M, Popov VL, Xiao SY. Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus. Emerg Infect Dis. 2004 Sep;10(9):1563. doi: 10.3201/EID1009.040310.
Harris E. What to know about monkeypox. Jama. 2022 Jun 21;327(23):2278-9. doi: 10.1001/JAMA.2022.9499.
Walter K, Malani PN. What is monkeypox? Jama. 2022 Jul 12;328(2):222. doi: 10.1001/JAMA.2022.10259.
Guarner J, Del Rio C, Malani PN. Monkeypox in 2022—what clinicians need to know. Jama. 2022 Jul 12;328(2):139-40. doi: 10.1016/S2666-5247(23)00034-4.
Upadhayay S, Arthur R, Soni D, Yadav P, Navik U, Singh R, et al. Monkeypox infection: The past, present, and future. Int. Immunopharmacol. 2022 Dec 1;113:109382. doi: 10.1016/J.INTIMP.2022.109382.
Adler H, Taggart R. Monkeypox exposure during pregnancy: what does UK public health guidance advise?. Lancet. 2022 Oct 29;400(10362):1509. doi: 10.1016/S0140-6736(22)01794-9.
Billioux BJ, Mbaya OT, Sejvar J, Nath A. Potential complications of monkeypox. The Lancet Neurol. 2022 Oct 1;21(10):872. doi: 10.1016/S1474-4422(22)00340-4.
Durski KN. Emergence of monkeypox—west and central Africa, 1970–2017. MMWR Morb Mortal Wkly Rep. 2018;67. doi: 10.1097/INF.0000000000002074.
Wang Y, Leng P, Zhou H. Global transmission of monkeypox virus—a potential threat under the COVID-19 pandemic. Front. Immunol. 2023 May 5;14:1174223. doi: 10.3389/FIMMU.2023.1174223.
Kumar P, Chaudhary B, Yadav N, Devi S, Pareek A, Alla S, et al. Recent advances in research and management of human Monkeypox virus: an emerging global health threat. Viruses. 2023 Apr 10;15(4):937. doi: 10.3390/V15040937.
Meo SA, Alsomali AH, Almushawah AA, Meo AS. Epidemiological trends of human monkeypox cases in northern, southern, western, and eastern regions in europe: a cross‐sectional study. J Trop Med. 2022;2022(1):4042962. doi: 10.1155/2022/4042962.
Weppelmann TA, Wadia HP, Espana EM. Large conjunctival ulceration from ocular monkeypox. Am. J. Ophthalmol. 2023 Apr 1;248:e2. doi: 10.1016/J.AJO.2023.01.027.
Del Rio C, Malani PN. Update on the monkeypox outbreak. JAMA. 2022 Sep 13;328(10):921-2. doi: 10.1001/JAMA.2022.14857.
Aden D, Zaheer S, Kumar R, Ranga S. Monkeypox (Mpox) outbreak during COVID‐19 pandemic—Past and the future. J Med Virol. 2023 Apr;95(4):e28701. doi: 10.1002/JMV.28701.
Guarner J, Del Rio C, Malani PN. Monkeypox in 2022—what clinicians need to know. Jama. 2022 Jul 12;328(2):139-40. doi: 10.1001/JAMA.2022.10802.
Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, et al. Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emerg. Infect. Dis. 2016 Jun;22(6):1014. doi: 10.3201/EID2206.150579.
Accordini S, Cordioli M, Pomari E, Tacconelli E, Castilletti C. People with asymptomatic or unrecognised infection potentially contribute to monkeypox virus transmission. The Lancet Microbe. 2023 Apr 1;4(4):e209. doi: 10.1016/S2666-5247(22)00379-2.
Reda A, El-Qushayri AE, Shah J. Asymptomatic monkeypox infection: a call for greater control of infection and transmission. The Lancet Microbe. 2023 Jan 1;4(1):e15-6. doi: 10.1016/S2666-5247(22)00259-2.
Siordia Jr JA. Epidemiology and clinical features of COVID-19: A review of current literature. J Clin Virol. 2020 Jun 1;127:104357. doi: 10.1016/j.jcv.2020.104357.
Bisanzio D, Reithinger R. Projected burden and duration of the 2022 Monkeypox outbreaks in non-endemic countries. The Lancet Microbe. 2022 Sep 1;3(9):e643. doi: 10.1016/S2666-5247(22)00183-5.
Colavita F, Antinori A, Nicastri E, Focosi D, Girardi E, Vaia F, et al. Monkeypox virus in human body sites and fluids: evidence for transmission. Lancet Infect Dis. 2022 Sep 29;23(1):6. Doi: 10.1016/S1473-3099(22)00639-9.
Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, de Coul EO, et al. Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022. Euro Surveill. 2022 Jun 16;27(24):2200448. doi: 10.2807/1560-7917.ES.2022.27.24.2200448.
Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini LE, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Euro Surveill. 2022 Jun 2;27(22):2200421. doi: 10.2807/1560-7917.ES.2022.27.22.2200421.
Bragazzi NL, Kong JD, Mahroum N, Tsigalou C, Khamisy‐Farah R, Converti M, et al. Epidemiological trends and clinical features of the ongoing monkeypox epidemic: a preliminary pooled data analysis and literature review. J Med Virol. 2023 Jan;95(1):e27931. doi: 10.1002/JMV.27931.
Li H, Zhang H, Ding K, Wang XH, Sun GY, Liu ZX, et al. The evolving epidemiology of monkeypox virus. Cytokine Growth Factor Rev. 2022 Dec 1;68:1-2. doi: 10.1016/J.CYTOGFR.2022.10.002.
Condit RC, Moussatche N, Traktman P. In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res. 2006 Jan 1;66:31-124. doi: 10.1016/S0065-3527(06)66002-8.
Shchelkunov SN, Totmenin AV, Safronov PF, Mikheev MV, Gutorov VV, Ryazankina OI, et al. Analysis of the monkeypox virus genome. Virology. 2002 Jun 5;297(2):172-94. doi: 10.1006/viro.2002.1446.
Garon CF, Barbosa E, Moss B. Visualization of an inverted terminal repetition in vaccinia virus DNA. Proc Natl Acad Sci. 1978 Oct;75(10):4863-7. doi: 10.1073/PNAS.75.10.4863.
Wittek R, Menna A, Müller HK, Schümperli D, Boseley PG, Wyler R. Inverted terminal repeats in rabbit poxvirus and vaccinia virus DNA. J Virol. 1978 Oct;28(1):171-81. doi: 10.1128/JVI.28.1.171-181.1978.
Shchelkunov SN, Totmenin AV, Babkin IV, Safronov PF, Ryazankina OI, Petrov NA, et al. Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett. 2001 Nov 30;509(1):66-70. doi: 10.1016/S0014-5793(01)03144-1.
Andrei G, Snoeck R. Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development. Trends Pharmacol. Sci. 2023 Sep 4. doi: 10.1016/J.TIPS.2023.08.003.
Desingu PA, Rubeni TP, Nagarajan K, Sundaresan NR. Molecular evolution of 2022 multi-country outbreak-causing monkeypox virus Clade IIb. Iscience. 2024 Jan 19;27(1). doi: 10.1016/J.ISCI.2023.108601.
Ndodo N, Ashcroft J, Lewandowski K, Yinka-Ogunleye A, Chukwu C, Ahmad A, et al. Distinct monkeypox virus lineages co-circulating in humans before 2022. Nat Med. 2023 Sep;29(9):2317-24. doi: 10.1038/S41591-023-02456-8.
Wang L, Shang J, Weng S, Aliyari SR, Ji C, Cheng G, et al. Genomic annotation and molecular evolution of monkeypox virus outbreak in 2022. J Med Virol. 2023 Jan;95(1):e28036. doi: 10.1002/JMV.28036.
Haller SL, Peng C, McFadden G, Rothenburg S. Poxviruses and the evolution of host range and virulence. Infect Genet Evol. 2014 Jan 1;21:15-40. doi: 10.1016/J.MEEGID.2013.10.014.
Locker JK, Kuehn A, Schleich S, Rutter G, Hohenberg H, Wepf R, et al. Entry of the two infectious forms of vaccinia virus at the plasma membane is signaling-dependent for the IMV but not the EEV. Mol Biol Cell. 2000 Jul 1;11(7):2497-511. doi: 10.1091/MBC.11.7.2497.
Moss B. Membrane fusion during poxvirus entry. Cell Dev Biol. 2016 Dec 1;60:89-96. doi: 10.1016/J.SEMCDB.2016.07.015.
Vanderplasschen A, Hollinshead M, Smith GL. Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol. 1998 Apr;79(4):877-87. doi: 10.1099/0022-1317-79-4-877.
Ichihashi Y. Extracellular enveloped vaccinia virus escapes neutralization. Virology. 1996 Mar 15;217(2):478-85. doi: 10.1006/VIRO.1996.0142.
Simons K, Toomre D. Lipid rafts and signal transduction. Cell Biol. 2000 Oct 1;1(1):31-9. doi: 10.1038/35036052.
Sekaran S, Sekar SK. Repurposing cholesterol lowering drugs in the treatment and management of monkeypox. Int J Surg. 2023 Jan 1;109(1):60-1. doi: 10.1097/JS9.0000000000000010.
He P, Shi D, Li Y, Xia K, Kim SB, Dwivedi R, et al. SPR sensor-based analysis of the inhibition of marine sulfated glycans on interactions between Monkeypox virus proteins and glycosaminoglycans. Mar. Drugs .2023 Apr 25;21(5):264. doi: 10.3390/MD21050264.
Li M, Ren Z, Wang Y, Jiang Y, Yang M, Li D, et al. Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus. Emerg Microbes Infect. 2023 Dec 8;12(2):2223669. doi: 10.1080/22221751.2023.2223669.
Dsouza L, Pant A, Offei S, Priyamvada L, Pope B, Satheshkumar PS, et al. Antiviral activities of two nucleos (t) ide analogs against vaccinia and mpox viruses in primary human fibroblasts. BioRxiv. 2023 Mar 23. doi: 10.1101/2023.03.23.533943.
Johnson KA, Dangerfield T. Mechanisms of inhibition of viral RNA replication by nucleotide analogs. Enzym. 2021 Jan 1;49:39-62. doi: 10.1016/BS.ENZ.2021.07.001.
Wang W, Li B, Wu Y, Li M, Ma S, Yan D, et al. Macrophage-derived biomimetic nanoparticles for light-driven theranostics toward Mpox. Matter. 2024 Mar 6;7(3):1187-206. doi: 10.1016/J.MATT.2024.01.004.
Andrei G, Snoeck R. Cidofovir activity against poxvirus infections. Viruses. 2010 Dec 22;2(12):2803. doi: 10.3390/V2122803.
Smee DF, Bailey KW, Sidwell RW. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir Chem Chemother. 2000 Aug;11(4):303-9. doi: 10.1177/095632020001100406.
Coen N, Duraffour S, Haraguchi K, Balzarini J, van den Oord JJ, Snoeck R, et al. Antiherpesvirus activities of two novel 4′-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases. Antimicrob Agents Chemother. 2014 Aug;58(8):4328-40. doi: 10.1128/AAC.02825-14.
Priyamvada L, Alabi P, Leon A, Kumar A, Sambhara S, Olson VA, et al. Discovery of Retro-1 analogs exhibiting enhanced anti-vaccinia virus activity. Front Microbiol. 2020 Apr 23;11:603. doi: 10.3389/FMICB.2020.00603.
See KC. Vaccination for monkeypox virus infection in humans: a review of key considerations. Vaccines. 2022 Aug 18;10(8):1342. doi: 10.3390/VACCINES10081342.
Abrahams BC, Kaufman DM. Anticipating smallpox and monkeypox outbreaks: complications of the smallpox vaccine. Neurologist. 2004 Sep 1;10(5):265-74. doi: 10.1097/01.nrl.0000138998.11209.88.
Jezek Z, Marennikova SS, Mutumbo M, Nakano JH, Paluku KM, Szczeniowski M. Human monkeypox: a study of 2,510 contacts of 214 patients. J Infect Dis. 1986 Oct 1;154(4):551-5. doi: 10.1093/INFDIS/154.4.551.
Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 2003 Sep 1;9(9):1125-30. doi: 10.1038/NM916.
Decker MD, Garman PM, Hughes H, Yacovone MA, Collins LC, Fegley CD, et al. Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members. Vaccine. 2021 Sep 15;39(39):5541-7. doi: 10.1016/J.VACCINE.2021.08.041.
Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults. Vaccine. 2009 Mar 4;27(10):1637-44. doi: 10.1016/J.VACCINE.2008.11.079.
Garcia-Atutxa I, Mondragon-Teran P, Huerta-Saquero A, Villanueva-Flores F. Advancements in monkeypox vaccines development: a critical review of emerging technologies. Front Immunol. 2024 Oct 11;15:1456060. doi: 10.3389/fimmu.2024.1456060.
Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005 Oct 15;79(20):13139-49. doi: 10.1128/JVI.79.20.13139-13149.2005.
Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08.
Kabanov AS, Sergeev AA, Shishkina LN, Bulychev LE, Skarnovich MO, Bormotov NI, et al. A comparative study of the antiviral activity of chemical compounds concerning the orthopoxviruses experiments in vivo. Vopr Virusol. 2013 Jul 1;58(4):39-43. https://europepmc.org/article/MED/24354064
Smith SK, Olson VA, Karem KL, Jordan R, Hruby DE, Damon IK. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother. 2009 Mar;53(3):1007-12. doi: 10.1128/AAC.01044-08.
De Clercq E. Historical perspectives in the development of antiviral agents against poxviruses. Viruses. 2010 Jun 14;2(6):1322-39. doi: 10.3390/V2061322.
Blasco RA, Moss BE. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol. 1991 Nov;65(11):5910-20. doi: 10.1128/JVI.65.11.5910-5920.1991.
Wittek R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis. 2006 May 1;10(3):193-201. doi: 10.1016/J.IJID.2005.12.001.
Whitehouse ER. Novel treatment of a vaccinia virus infection from an occupational needlestick—San Diego, California, 2019. MMWR Morb Mortal Wkly Rep. 2019;68. doi: 10.15585/MMWR.MM6842A2.
Lindholm DA, Fisher RD, Montgomery JR, Davidson W, Yu PA, Yu YC, et al. Preemptive tecovirimat use in an active duty service member who presented with acute myeloid leukemia after smallpox vaccination. Clin Infect Dis. 2019 Nov 27;69(12):2205-7. doi: 10.1093/CID/CIZ286.
Hatch GJ, Graham VA, Bewley KR, Tree JA, Dennis M, Taylor I, et al. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol. 2013 Jul 15;87(14):7805-15. doi: 10.1128/JVI.03481-12.
Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. N Engl J Med. 2019 Nov 14;381(20):1897-908. doi: 10.1056/NEJMOA1817307.
Zaeck LM, Lamers MM, Verstrepen BE, Bestebroer TM, Van Royen ME, Götz H, et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med. 2023 Jan;29(1):270-8. doi: 10.1038/s41591-022-02090-w.
Sah R, Humayun M, Baig E, Farooq M, Hussain HG, Shahid MU, et al. FDA's authorized “JYNNEOS” vaccine for counteracting monkeypox global public health emergency; an update–Correspondence. Int J Surg. 2022 Nov 1;107:106971. Doi. org/10.1016/j.ijsu.2022.106971.
Brooks JT, Marks P, Goldstein RH, Walensky RP. Intradermal vaccination for monkeypox—benefits for individual and public health. N Engl J Med. 2022 Sep 29;387(13):1151-3. doi: 10.1056/NEJMp2211311.
Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, El Sahly H, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine. 2015 Sep 22;33(39):5225-34. doi: 10.1016/J.VACCINE.2015.06.075.
108. Kumbhar N, Agarwala P. The lurking threat of monkeypox in current times. Indian J Med Microbiol. 2022 Oct 1;40(4):475-9. doi: 10.1016/j.ijmmb.2022.07.016.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).